Infrascan’s handheld scanner landed FDA de novo approval to help first responders detect brain bleeds in patients who have undergone a traumatic head injury.
The Infrascanner Model 1000 uses near-infrared imaging to detect bleeds at an injury site within the "golden hour," the period following head trauma when pre-hospital analysis is critical.
"While patients with suspected brain injuries routinely receive a CT scan, this portable device offers emergency room physicians a non-invasive mechanism to aid in assessing whether an immediate CT scan is needed," Christy Foreman, of the FDA’s Center for Devices & Radiological Health, said in prepared remarks.
The federal watchdog agency approved the Infrascanner through the "de novo" classification process, a pathway designed for low-risk medical devices that can’t be compared to devices currently on the market.
In a 383-patient study, the Philadelphia-based company’s handheld scanner detected nearly 75 percent of brain bleeds detected by a computed tomography scan. When CT scans detected no hematoma, neither did the Infrascanner 82 percent of the time.
The federal watchdog agency stressed that the Infrascanner Model 1000 is not a replacement for a standard CT scan.
Gallbladder removal bot lands FDA approval
Sunnyvale, Calif.-based Intuitive Surgical’s da Vinci Si robot landed FDA approval for single-site laparoscopic gallbladder removal. Read more
St. Jude launches European clinical trials
St. Jude Medical announced the first implant of its Portico transcatheter aortic valve implant in a European trial. The clinical trial will support a bid for CE Mark approval. Read more
Spinal neurostimulator receives CE Mark
The Spinal Modulation Neurostimulator system won CE Mark approval for the management of chronic intractable pain. Read more
EnteroMedics touts Australian regulatory win
Weight loss device maker EnteroMedics Inc. landed Australian Therapeutic Goods Administration approval for its Maestro weight loss treatment. Read more